Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof
View Patent ↗This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
1. A method for treating a human condition, disorder or disease mediated in whole or in part by CD40 signaling, or a symptom of any of the foregoing, the method comprising the step of administering to a subject in need thereof a therapeutically effective amount of a CD154 binding protein comprising heavy chain CDR1, CDR2 and CDR3 sequences selected from:
(a) SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively;
(b) SEQ ID NO: 42, SEQ ID NO: 43 and SEQ ID NO: 44, respectively; or
(c) SEQ ID NO: 48, SEQ ID NO: 49 and SEQ ID NO: 50, respectively;
and comprising light chain CDR1, CDR2 and CDR3 sequences selected from:
(a) SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, respectively;
(b) SEQ ID NO: 45, SEQ ID NO: 46 and SEQ ID NO: 47, respectively; or
(c) SEQ ID NO: 51, SEQ ID NO: 52 and SEQ ID NO: 53, respectively,
wherein the condition, disorder or disease is an inflammatory or autoimmune response or fibrosis.
2. The method according to claim 1 , wherein the inflammatory or autoimmune response or fibrosis is selected from lupus nephritis, rheumatoid arthritis, systemic lupus erythematosis, spondyloarthritis, inflammatory bowel disease, Crohn's disease, psoriasis and multiple sclerosis.
3. A method for treating a human condition, disorder or disease mediated in whole or in part by CD40 signaling, or a symptom of any of the foregoing, the method comprising the step of administering to a subject in need thereof a therapeutically effective amount of a composition of a CD154 binding protein comprising heavy chain CDR1, CDR2 and CDR3 sequences selected from:
(a) SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively;
(b) SEQ ID NO: 42, SEQ ID NO: 43 and SEQ ID NO: 44, respectively; or
(c) SEQ ID NO: 48, SEQ ID NO: 49 and SEQ ID NO: 50, respectively;
and comprising light chain CDR1, CDR2 and CDR3 sequences selected from:
(a) SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, respectively;
(b) SEQ ID NO: 45, SEQ ID NO: 46 and SEQ ID NO: 47, respectively; or
(c) SEQ ID NO: 51, SEQ ID NO: 52 and SEQ ID NO: 53, respectively,
wherein the condition, disorder or disease is an inflammatory or autoimmune response or fibrosis.
4. The method according to claim 3 , wherein the inflammatory or autoimmune response or fibrosis is selected from rheumatoid arthritis, systemic lupus erythematosis, drug-induced lupus erythematosus, lupus nephritis, spondyloarthritis, inflammatory bowel disease, Crohn's disease, psoriasis and multiple sclerosis.
5. The method according to claim 4 , wherein said inflammatory or autoimmune response or fibrosis is lupus nephritis.
6. The method according to claim 4 , wherein said inflammatory or autoimmune response or fibrosis is systemic lupus erythematosis.
7. The method according to claim 4 , wherein said inflammatory or autoimmune response or fibrosis is drug-induced lupus erythematosus.